Research
Hormonal
Bariatric surgery (specifically metabolic procedures like Roux-en-Y gastric bypass) produces greater diabetes remission and weight loss than purely restrictive procedures (like gastric banding) due to hormonal and neural changes.
If you have extreme obesity, metabolic surgery (like gastric bypass) is more effective than restrictive surgery (like bands) for curing diabetes and losing weight because it changes your gut hormones, not just your stomach size. Discuss with a specialist if you are a candidate.
GoodSupportsHIGH confidence
The latter approaches ('metabolic' surgery) appear to produce unique effects on enteroendocrine hormones and neuronal signaling pathways and produce more weight loss and diabetes remission than banding alone.
Why this rating
Based on expert consensus and nonrandomized studies cited in the text.
Source
Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
Robert H. Eckel et al. · The Journal of Clinical Endocrinology & Metabolism · 2011
DOI 10.1210/jc.2011-0585
narrative_reviewCited 549×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity and type 2 diabetes share a pathogenesis involving nutrient excess, inflammation, and mitochondrial dysfunction, leading to insulin resistance and beta-cell failure.Strong
- Modest weight reduction (5-10%) achieved through lifestyle interventions, pharmacotherapy, or bariatric surgery improves glycemic control and reduces type 2 diabetes risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →